Using human-induced pluripotent stem cells to model monogenic metabolic disorders of the liver

Seminars in Liver Disease

Volumn 32, Issue 4, 2012, Pages 298-306

  Ordonez, Maria Paulina ^a   Goldstein, Lawrence S B ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cell transplantation; disease modeling; hepatocyte differentiation; human induced pluripotent stem cells; inherited liver metabolic disorders

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL LINEAGE; CELL POPULATION; CELL TRANSPLANTATION; EMBRYONIC STEM CELL; FAMILIAL HYPERCHOLESTEROLEMIA; GLYCOGEN STORAGE DISEASE TYPE 1; HEPATOCYTE TRANSPLANTATION; HUMAN; HUMAN CELL; LIVER CELL; LIVER DISEASE; LIVER METABOLISM; METABOLIC DISORDER; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL;

ALPHA 1-ANTITRYPSIN DEFICIENCY; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL TRANSPLANTATION; GLYCOGEN STORAGE DISEASE TYPE I; HEPATOCYTES; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INDUCED PLURIPOTENT STEM CELLS; LIVER DISEASES; METABOLISM, INBORN ERRORS; MODELS, BIOLOGICAL;

EID: 84873362963     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0032-1329898     Document Type: Article

References (104)

1. Mayatepek E., Hoffmann B., Meissner T. Inborn errors of carbohydrate metabolism. Best Pract Res Clin Gastroenterol: 2010; 24 5 607 618
2. Bechmann L. P., Hannivoort R. A., Gerken G., Hotamisligil G. S., Trauner M., Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol: 2012; 56 4 952 964
3. Lerapetritou M. G., Georgopoulos P. G., Roth C. M., Androulakis L. P. Tissue-level modeling of xenobiotic metabolism in liver: An emerging tool for enabling clinical translational research. Clin Transl Sci: 2009; 2 3 228 237
4. Lanpher B., Brunetti-Pierri N., Lee B. Inborn errors of metabolism: the flux from Mendelian to complex diseases. Nat Rev Genet: 2006; 7 6 449 460 (Pubitemid 43780488)
5. Melum E., Franke A., Karlsen T. H. Genome-wide association studies-a summary for the clinical gastroenterologist. World J Gastroenterol: 2009; 15 43 5377 5396
6. Weber S. L., Segal S., Packman W. Inborn errors of metabolism: psychosocial challenges and proposed family systems model of intervention. Mol Genet Metab: 2012; 105 4 537 541
7. Sokal E. M. Liver transplantation for inborn errors of liver metabolism. J Inherit Metab Dis: 2006; 29 2-3 426 430 (Pubitemid 43880646)
8. Meyburg J., Hoffmann G. F. Liver cell transplantation for the treatment of inborn errors of metabolism. J Inherit Metab Dis: 2008; 31 164 172
9. Larter C. Z., Yeh M. M. Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol: 2008; 23 11 1635 1648
10. van der Worp H. B., Howells D. W., Sena E. S., et al. Can animal models of disease reliably inform human studies? PLoS Med: 2010; 7 3 e1000245
11. Colman A., Dreesen O. Pluripotent stem cells and disease modeling. Cell Stem Cell: 2009; 5 3 244 247
12. Jucker M. The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med: 2010; 16 11 1210 1214
13. Wong P. C., Cai H., Borchelt D. R., Price D. L. Genetically engineered mouse models of neurodegenerative diseases. Nat Neurosci: 2002; 5 7 633 639 (Pubitemid 34742978)
14. Dawson T. M., Ko H. S., Dawson V. L. Genetic animal models of Parkinson's disease. Neuron: 2010; 66 5 646 661
15. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell: 2006; 126 4 663 676 (Pubitemid 44233629)
16. Takahashi K., Tanabe K., Ohnuki M., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell: 2007; 131 5 861 872 (Pubitemid 350138099)
17. Park I-H, Zhao R., West J. A., et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature: 2008; 451 7175 141 146
18. Cohen D. E., Melton D. Turning straw into gold: directing cell fate for regenerative medicine. Nat Rev Genet: 2011; 12 4 243 252
19. Gurdon J. B., Melton D. A. Nuclear reprogramming in cells. Science: 2008; 322 5909 1811 1815
20. Ying Q. L., Wray J., Nichols J., et al. The ground state of embryonic stem cell self-renewal. Nature: 2008; 453 7194 519 523 (Pubitemid 351733324)
21. Blau H. M., Brazelton T. R., Weimann J. M. The evolving concept of a stem cell: entity or function? Cell: 2001; 105 7 829 841 (Pubitemid 32635085)
22. Izpisúa Belmonte J. C., Ellis J., Hochedlinger K., Yamanaka S. Induced pluripotent stem cells and reprogramming: seeing the science through the hype. Nat Rev Genet: 2009; 10 12 878 883
23. Robinton D. A., Daley G. Q. The promise of induced pluripotent stem cells in research and therapy. Nature: 2012; 481 7381 295 305
24. Stadtfeld M., Hochedlinger K. Induced pluripotency: history, mechanisms, and applications. Genes Dev: 2010; 24 20 2239 2263
25. Maherali N., Hochedlinger K. Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell: 2008; 3 6 595 605
26. Park I-H, Arora N., Huo H., et al. Disease-specific induced pluripotent stem cells. Cell: 2008; 134 5 877 886
27. Maehr R., Chen S., Snitow M., et al. Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci U S A: 2009; 106 37 15768 15773
28. Mou X., Wu Y., Cao H., et al. Generation of disease-specific induced pluripotent stem cells from patients with different karyotypes of Down syndrome. Stem Cell Res Ther: 2012; 3 2 14
29. Sánchez-Danés A., Richaud-Patin Y., Carballo-Carbajal I., et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Molecular Medicine: 2012; 4 1 16
30. Schwartz R. E., Trehan K., Andrus L., et al. Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci U S A: 2012; 109 7 2544 2548
31. Yusa K., Rashid S. T., Strick-Marchand H., et al. Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature: 2011; 478 7369 391 394
32. Fairbanks K. D., Tavill A. S. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol: 2008; 103 8 2136 2141, quiz 2142
33. Fregonese L., Stolk J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis: 2008; 3 16
34. Perlmutter D. H., Brodsky J. L., Balistreri W. F., Trapnell B. C. Molecular pathogenesis of alpha-1-antitrypsin deficiency-associated liver disease: a meeting review. Hepatology: 2007; 45 5 1313 1323 (Pubitemid 46775796)
35. Petit I., Kesner N. S., Karry R., et al. Induced pluripotent stem cells from hair follicles as a cellular model for neurodevelopmental disorders. Stem Cell Res (Amst): 2012; 8 1 134 140
36. Yan X., Qin H., Qu C., Tuan R. S., Shi S., Huang G. T. iPS cells reprogrammed from human mesenchymal-like stem/progenitor cells of dental tissue origin. Stem Cells Dev: 2010; 19 4 469 480
37. Kim K., Doi A., Wen B., et al. Epigenetic memory in induced pluripotent stem cells. Nature: 2010; 467 7313 285 290
38. Nishino K., Toyoda M., Yamazaki-Inoue M., et al. DNA methylation dynamics in human induced pluripotent stem cells over time. PLoS Genet: 2011; 7 5 e1002085
39. Saha K., Jaenisch R. Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell: 2009; 5 6 584 595
40. Kaji K., Norrby K., Paca A., Mileikovsky M., Mohseni P., Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature: 2009; 458 7239 771 775
41. Zhou W., Freed C. R. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells: 2009; 27 11 2667 2674
42. Cheng L., Hansen N. F., Zhao L., et al. NISC Comparative Sequencing Program Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression. Cell Stem Cell: 2012; 10 3 337 344
43. Woltjen K., Michael I. P., Mohseni P., et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature: 2009; 458 7239 766 770
44. Boulting G. L., Kiskinis E., Croft G. F., et al. A functionally characterized test set of human induced pluripotent stem cells. Nat Biotechnol: 2011; 29 3 279 286
45. Miura K., Okada Y., Aoi T., et al. Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol: 2009; 27 8 743 745
46. Urnov F. D., Miller J. C., Lee Y-L., et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature: 2005; 435 7042 646 651 (Pubitemid 40825505)
47. Hockemeyer D., Wang H., Kiani S., et al. Genetic engineering of human pluripotent cells using TALE nuclease. Nat Biotechnol: 2011; 29 8 731 734
48. Gonzalez F. J., Nebert D. W. Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation. Trends Genet: 1990; 6 6 182 186
49. Lin J. H. Species similarities and differences in pharmacokinetics. Drug Metab Dispos: 1995; 23 10 1008 1021
50. Wilkinson G. R. Drug metabolism and variability among patients in drug response. N Engl J Med: 2005; 352 21 2211 2221
51. Hamazaki T., Iiboshi Y., Oka M., et al. Hepatic maturation in differentiating embryonic stem cells in vitro. FEBS Lett: 2001; 497 1 15 19 (Pubitemid 32480173)
52. Chinzei R., Tanaka Y., Shimizu-Saito K., et al. Embryoid-body cells derived from a mouse embryonic stem cell line show differentiation into functional hepatocytes. Hepatology: 2002; 36 1 22 29 (Pubitemid 34700758)
53. Touboul T., Hannan N. RF, Corbineau S., et al. Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology: 2010; 51 5 1754 1765
54. Cai J., Zhao Y., Liu Y., et al. Directed differentiation of human embryonic stem cells into functional hepatic cells. Hepatology: 2007; 45 5 1229 1239 (Pubitemid 46775786)
55. Murry C. E., Keller G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell: 2008; 132 4 661 680 (Pubitemid 351260059)
56. Irion S., Nostro M. C., Kattman S. J., Keller G. M. Directed differentiation of pluripotent stem cells: from developmental biology to therapeutic applications. Cold Spring Harb Symp Quant Biol: 2008; 73 101 110
57. Behbahan I. S., Duan Y., Lam A., et al. New approaches in the differentiation of human embryonic stem cells and induced pluripotent stem cells toward hepatocytes. Stem Cell Rev: 2011; 7 3 748 759
58. Gai H., Nguyen D. M., Moon Y. J., et al. Generation of murine hepatic lineage cells from induced pluripotent stem cells. Differentiation: 2010; 79 3 171 181
59. Duan Y., Ma X., Zou W., et al. Differentiation and characterization of metabolically functioning hepatocytes from human embryonic stem cells. Stem Cells: 2010; 28 4 674 686
60. Asgari S., Moslem M., Bagheri-Lankarani K., et al. Differentiation and transplantation of human induced pluripotent stem cell-derived hepatocyte-like cells. Stem Cell Rev: 2011; Nov 11. [Epub ahead of print]
61. D'Amour K. A., Agulnick A. D., Eliazer S., Kelly O. G., Kroon E., Baetge E. E. Efficient differentiation of human embryonic stem cells to definitive endoderm. Nat Biotechnol: 2005; 23 12 1534 1541 (Pubitemid 41752931)
62. Farzaneh Z., Pournasr B., Ebrahimi M., Aghdami N., Baharvand H. Enhanced functions of human embryonic stem cell-derived hepatocyte-like cells on three-dimensional nanofibrillar surfaces. Stem Cell Rev: 2010; 6 4 601 610
63. Ek M., Söderdahl T., Küppers-Munther B., et al. Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. Biochem Pharmacol: 2007; 74 3 496 503 (Pubitemid 46970845)
64. Agarwal S., Holton K. L., Lanza R. Efficient differentiation of functional hepatocytes from human embryonic stem cells. Stem Cells: 2008; 26 5 1117 1127
65. Yamada T., Yoshikawa M., Kanda S., et al. In vitro differentiation of embryonic stem cells into hepatocyte-like cells identified by cellular uptake of indocyanine green. Stem Cells: 2002; 20 2 146 154 (Pubitemid 34297262)
66. Basma H., Soto-Gutiérrez A., Yannam G. R., et al. Differentiation and transplantation of human embryonic stem cell-derived hepatocytes. Gastroenterology: 2009; 136 3 990 999
67. Song Z., Cai J., Liu Y., et al. Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. Cell Res: 2009; 19 11 1233 1242
68. Sullivan G. J., Hay D. C., Park I-H., et al. Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology: 2010; 51 1 329 335
69. Si-Tayeb K., Noto F. K., Nagaoka M., et al. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology: 2010; 51 1 297 305
70. Sekiya S., Suzuki A. Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature: 2011; 475 7356 390 393
71. Huang P., He Z., Ji S., et al. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature: 2011; 475 7356 386 389
72. Willenbring H. A simple code for installing hepatocyte function. Cell Stem Cell: 2011; 9 2 89 91
73. Eggenschwiler R., Loya K., Sgodda M., André F., Cantz T. Hepatic differentiation of murine disease-specific induced pluripotent stem cells allows disease modelling in vitro. Stem Cells Int: 2011; 2011 924782 1 11
74. Grompe M. Liver repopulation for the treatment of metabolic diseases. J Inherit Metab Dis: 2001; 24 2 231 244 (Pubitemid 32479417)
75. Perlmutter D. H. Autophagic disposal of the aggregation-prone protein that causes liver inflammation and carcinogenesis in α-1-antitrypsin deficiency. Cell Death Differ: 2009; 16 1 39 45
76. Teckman J. H., An J. K., Blomenkamp K., Schmidt B., Perlmutter D. Mitochondrial autophagy and injury in the liver in alpha 1-antitrypsin deficiency. Am J Physiol Gastrointest Liver Physiol: 2004; 286 5 G851 G862 (Pubitemid 38506818)
77. Perlmutter D. H. The role of autophagy in alpha-1-antitrypsin deficiency: a specific cellular response in genetic diseases associated with aggregation-prone proteins. Autophagy: 2006; 2 4 258 263 (Pubitemid 44342367)
78. Rashid S. T., Corbineau S., Hannan N., et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest: 2010; 120 9 3127 3136
79. Wilson M. H., Coates C. J., George A. L. Jr. PiggyBac transposon-mediated gene transfer in human cells. Mol Ther: 2007; 15 1 139 145 (Pubitemid 46043659)
80. Kim A., Pyykko I. Size matters: versatile use of PiggyBac transposons as a genetic manipulation tool. Mol Cell Biochem: 2011; 354 1-2 301 309
81. Mundy H., Lee P. J. The glycogen storage diseases. Curr Paediatr: 2004; 14 407 413 (Pubitemid 39094459)
82. Ozen H. Glycogen storage diseases: new perspectives. World J Gastroenterol: 2007; 13 18 2541 2553 (Pubitemid 46938823)
83. Chou J. Y., Jun H. S., Mansfield B. C. Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy. Nat Rev Endocrinol: 2010; 6 12 676 688
84. Davis M. K., Weinstein D. A. Liver transplantation in children with glycogen storage disease: controversies and evaluation of the risk/benefit of this procedure. Pediatr Transplant: 2008; 12 2 137 145 (Pubitemid 351326916)
85. Wang D. Q., Fiske L. M., Carreras C. T., Weinstein D. A. Natural history of hepatocellular adenoma formation in glycogen storage disease type I. J Pediatr: 2011; 159 3 442 446
86. Di Rocco M., Calevo M. G., Taro' M., Melis D., Allegri A. E., Parenti G. Hepatocellular adenoma and metabolic balance in patients with type Ia glycogen storage disease. Mol Genet Metab: 2008; 93 4 398 402
87. Heller S., Worona L., Consuelo A. Nutritional therapy for glycogen storage diseases. J Pediatr Gastroenterol Nutr: 2008; 47 01 S15 S21
88. Wolfsdorf J. I., Crigler J. F. Jr. Effect of continuous glucose therapy begun in infancy on the long-term clinical course of patients with type I glycogen storage disease. J Pediatr Gastroenterol Nutr: 1999; 29 2 136 143 (Pubitemid 30366162)
89. Ghosh A., Allamarvdasht M., Pan C-J., et al. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer. Gene Ther: 2006; 13 4 321 329 (Pubitemid 43223101)
90. Chou J. Y., Mansfield B. C. Gene therapy for type I glycogen storage diseases. Curr Gene Ther: 2007; 7 2 79 88 (Pubitemid 46681766)
91. Brunetti-Pierri N., Lee B. Gene therapy for inborn errors of liver metabolism. Mol Genet Metab: 2005; 86 1-2 13 24 (Pubitemid 41412158)
92. Dhawan A., Mitry R. R., Hughes R. D. Hepatocyte transplantation for liver-based metabolic disorders. J Inherit Metab Dis: 2006; 29 2-3 431 435 (Pubitemid 43880647)
93. Sjouke B., Kusters D. M., Kastelein J. JP, Hovingh G. K. Familial hypercholesterolemia: present and future management. Curr Cardiol Rep: 2011; 13 6 527 536
94. Fahed A. C., Nemer G. M. Familial hypercholesterolemia: the lipids or the genes? Nutr Metab (Lond): 2011; 8 1 23
95. Soutar A. K., Naoumova R. P. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med: 2007; 4 4 214 225 (Pubitemid 46502094)
96. Wiegman A., Hutten B. A., de Groot E., et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA: 2004; 292 3 331 337 (Pubitemid 38944256)
97. Liu E. T. Expression genomics and drug development: towards predictive pharmacology. Brief Funct Genomics Proteomics: 2005; 3 4 303 321 (Pubitemid 40468215)
98. Ghodsizadeh A., Taei A., Totonchi M., et al. Generation of liver disease-specific induced pluripotent stem cells along with efficient differentiation to functional hepatocyte-like cells. Stem Cell Rev: 2010; 6 4 622 632
99. Sokal E. M., Goldstein D., Ciocca M., et al. End-Stage Liver Disease Working Group End-stage liver disease and liver transplant: current situation and key issues. J Pediatr Gastroenterol Nutr: 2008; 47 2 239 246
100. Singal A. K., Duchini A. Liver transplantation in acute alcoholic hepatitis: Current status and future development. World J Hepatol: 2011; 3 8 215 218
101. Feng S., Si M., Taranto S. E., et al. Trends over a decade of pediatric liver transplantation in the United States. Liver Transpl: 2006; 12 4 578 584
102. McDiarmid S. V., Goodrich N. P., Harper A. M., Merion R. M. Liver transplantation for status 1: the consequences of good intentions. Liver Transpl: 2007; 13 5 699 707 (Pubitemid 46796542)
103. Piscaglia A. C., Campanale M., Gasbarrini A., Gasbarrini G. Stem cell-based therapies for liver diseases: state of the art and new perspectives. Stem Cells Int: 2010; 2010 259461 1 10
104. Mizuguchi T., Mitaka T., Katsuramaki T., Hirata K. Hepatocyte transplantation for total liver repopulation. J Hepatobiliary Pancreat Surg: 2005; 12 5 378 385 (Pubitemid 41662448)